WO2007084548A2

WO2007084548A2 - Viral treatment

Info

Publication number: WO2007084548A2
Application number: PCT/US2007/001210
Authority: WO
Inventors: Ruben G. Fabunan
Original assignee: Fil-Am Tech., Inc.
Priority date: 2006-01-18
Filing date: 2007-01-17
Publication date: 2007-07-26
Also published as: WO2007084548A3

Abstract

Common colds, influenza, Dengue fever, mumps, measles, hepatitis, rabies, conjunctivitis, chickenpox, herpes, and HIV infection are treated by IM injection of a mixture comprising a first ingredient selected from the group consisting of chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and a second ingredient selected from the group consisting of dexamethasone, flumethasone and betamethasone, or by IM injection of a mixture comprising a first ingredient selected from the group consisting of procaine, chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and a second ingredient selected from the group consisting of flumethasone and betamethasone. Compositions in accordance with the invention are administered to prevent HIV from attaching to and penetrating host cells, to penetrate sanctuary sites to inactivate HIV and to generate vaccines from inactivated HIV.

Description

Viral Treatment

Related Application

[01] The present application claims priority from and is a continuation-in-part of U.S. Provisional Patent Application 60/759,847 filed January 18, 2006.

Background of the Invention

[02] The present invention provides a method of treating Dengue fever, influenza, HIV infection, common colds, herpes, mumps, measles, hepatitis, conjunctivitis, rabies, and chickenpox. Viruses have been shown to cause the foregoing diffϊcult-to-treat diseases. The present invention represents an ongoing effort to find effective treatments (to prevent, cure or ameliorate symptoms) against these diseases.

Summary of the Invention

[03] Common colds, influenza, Dengue fever, mumps, measles, hepatitis, rabies, conjunctivitis, chickenpox, herpes, and HIV infection are treated by intramuscular (IM) injection of a composition comprising a first ingredient selected from the group consisting of chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and a second ingredient selected from the group consisting of dexamethasone, flumethasone and betamethasone. The above diseases are also treated by IM injection of a mixture comprising a first ingredient selected from the group consisting of procaine, chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and a second ingredient selected from the group consisting of flumethasone and betamethasone. The treatment may further comprise administration of an electrolyte solution such as Hydrite, PEDIALYTE, etc. In an embodiment, the hydration solution is about half a tablet of Hydrite in approximately 500 ml water. In addition, the patient is also treated by an antipyretic, such as calpol, paracetamol, aspirin, acetaminophen, ibuprofen, etc.

Detailed Description of the Invention

[04] The present invention is directed to the treatment of common colds, influenza, Dengue fever, mumps, measles, hepatitis, rabies, conjunctivitis, chickenpox, herpes, and HIV infection by IM injection of a mixture comprising a first ingredient selected from the group consisting of chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and a second ingredient selected from the group consisting of dexamethasone, flumethasone and betamethasone. The above-referenced diseases are also treated by IM injection of a mixture comprising a first ingredient selected from the group consisting of procaine, chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and a second ingredient selected from the group consisting of flumethasone and betamethasone. In the context of the present disclosure, the named ingredients also include therapeutically effective salts and hydrates, thereof. The treatment further comprises administration of an electrolyte solution such as Hydrite, PEDIALYTE, etc. Electrolytes can be administered orally or intravenously. In addition, the patient is also treated by administration of an antipyretic, such as calpol, paracetamol, aspirin, acetaminophen, ibuprofen, etc.

[05] The term "therapeutically effective salts or hydrates," as use herein, represents those salts or hydrates which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are correspond to a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. The salts can be prepared in-situ during the final isolation and purification of the compounds of the invention or separately by reacting the free base group with a suitable organic acid. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphersulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate. nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine and the like.

[06] Injectable mixtures of this invention comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), vegetable oils (such as olive oil), injectable organic esters (such as ethyl oleate) and suitable mixtures thereof. Proper fluidity may be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

[07] These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

[08] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Medical Experimentation and Application

[09] Below are documented case studies demonstrating successful treatments and/or cures.

[10] Case 1. After three days of fever, malaise and loss of appetite, a 13-year-old boy was diagnosed with Dengue Fever. The patient was IM injected with a 2 ml dose of a 9:1 mixture of chloroprocaine (20 mg/ml) and dexamethasone (4 mg/ml) mixture followed by a second dose 60 minutes later. In addition, the patient was treated with electrolyte solution (about 500 ml per day) and aspirin, as needed. The treatment was repeated a second day and a third day (each with a 90 minute interval), at which time, the temperature was normal, the malaise was not apparent, and the patient was able to resume normal daily activities.

[11] Case 2. After four days of vomiting, fever, malaise and loss of appetite, a 9-year- old girl was diagnosed with Dengue Fever. Treatment with an antipyretic (Calpol) and an antibiotic (Co-trimoxazol) provided no relief. The patient was IM injected with a 1 ml dose of a mixture of chloroprocaine and dexamethasone mixture followed by a second dose 60 minutes later. In addition, the patient was treated with electrolyte solution (500 ml water with ¹A electrolyte tablet) and paracetamol. The treatment was repeated a second and a third day, at which time, the temperature was normal, the malaise was not apparent, the patient had improved appetite, and the patient was able to resume normal daily activities.

[12] Case 3. After five days of fever, malaise, headaches, chills and loss of appetite, a 27-year-old man was diagnosed with influenza. Treatment with paracetamol (antipyretic) provided no relief. The patient was IM injected with a 2 ml dose of a 9:1 mixture of chloroprocaine (20 mg/ml) and dexamethasone (4 mg/ml) mixture. In addition, the patient was treated with electrolyte solution. The treatment was repeated a day later, at which time, the temperature and appetite was normal, and the patient was able to resume normal daily activities.

[13] Case 4. After four days of fever, malaise, headaches, loss of appetite and joint pains, a 73-year-old woman was diagnosed with influenza. Self-medication with Paracetamol (antipyretic) afforded no relief. The patient was IM injected with a 2 ml dose of a mixture of chloroprocaine and dexamethasone mixture. In addition, the patient was treated with oral electrolyte solution. The treatment was repeated a day later, at which time, the temperature and appetite was normal, the headache was gone, and the patient was able to resume normal daily activities.

[14] Case 5. A 36-year-old woman was diagnosed as positive for both HIV 1 and HIV 2. Both lungs were also co-infected with miliary tuberculosis (TB). The patient presented the following signs and symptoms: night sweating, swollen multiple glands around the neck and both axillas that were tender to touch. She also reported fatigability, lack of appetite, loss of weight, sleep disturbance and white mouth lesions. Upon intake, the patient stated that she was not taking any antiretroviral (ARV) drugs, but was in the midst of a six-month Rimactazid regimen for TB. Her immunodeficiency panel showed CD4 = 256 (N = 600-1500/mm of blood). The Cobas Ampliprep/Cobas Taqman showed a viral load of 526,000 copies / ml of plasma.

[15] The patient was administered an IM injection with a 1.5 ml dose of a 9:1 mixture of chloroprocaine (20mg/ml) and dexamethasone (4mg/ml) combination twice daily at an 1.5 hour interval for 15 days. The treatment was then tapered to 2 injections at a 1.5 hour interval on 4 days in week 3; 2 injections at a 1.5 hour interval on 3 days in week 4; 2 injections at a 1.5 hour interval on 2 days on week 5. The patient was also given 500 ml of bottled mineral water each day of treatment as an oral hydration solution.

[16] On a daily basis, the patient noticed no side-effects from the injections, but felt better in her daily activities. She reported an increase in appetite, better sleep patterns, absence of soreness around the neck and axillas, increase in energy, absence of mouth lesions and lymph glands that were no longer swollen and sensitive to touch. She had good skin turgor and her weight increased from 41.9 kg to 44.1 kg.

[17] Her 5^th week immunodeficiency panel showed CD4 = 399. The Cobas Ampliprep/Cobas Taqman showed a viral load of 1,483,770 copies / ml of plasma. It was noted that while the CD4 increased from 256 to 399, the viral load also increased from 526,000 to 1,483,770. The theoretical implications of this result will be discussed below.

[18] Case 6. A 27-year-old woman was diagnosed as positive for both HIV 1 and HIV 2. The patient presented the following signs and symptoms: fatigability, night sweating, insomnia, itching at the neck, swollen multiple glands. She also reported sleep disturbance, occasional asthma or sinusitis, and recurring mouth lesions. Upon intake, the patient indicted that she was not taking any antiretroviral (ARV) drugs, but was taking vitamins A, C and D orally. Her immunodeficiency panel showed CD4 = 369. The Cobas Ampliprep/Cobas Taqman showed a viral load of 78,658 copies / ml of plasma.

[19] The patient was administered an IM injection with a 2 ml dose of a 9;1 mixture of chloroprocaine (20mg/ml) and dexamethasone (4 mg/ml) combination twice daily at a 1.5 hour interval for 15 days. The treatment was then tapered to 2 injections at a 1.5 hour interval on 4 days in week 3; 2 injections at a 1.5 hour interval on 3 days in week 4; 2 injections at a 1.5 hour interval on two days in week 5. The patient was also given 500 ml of bottled mineral water each day of treatment as an oral hydration solution. [20] Day-by-day the patient noticed no side effects from the injections and felt better in her daily activities. She stated that her signs and symptoms were much improved. She reported less fatigue and more energy, no insomnia and no more itching of the neck. The lymph glands were reduced in size. She also indicated a better appetite and no more mouth lesions. She had good skin turgor and was in high spirits. A 5 week immunodeficiency panel flow cytometer repeat test showed CD4 = 439. The Cobas Ampliprep/Cobas Taqman showed viral load = 100,106 copies / ml of plasma. Once again, these surprising results will be discussed below.

Discussion

[21] As demonstrated by the case studies, the recited compositions provided efficacy in treating the recited diseases. More generally, an adult HIV patient is treated with between about 1-10 ml IM injection of a mixture comprising between about 0.6-9.5 ml of about 0.5-13% chloroprocaine and between about 0.1-8.7 ml of about 4 mg/ml dexamethasone sodium phosphate. In another embodiment, an adult HIV patient is treated with between about 0.1-10 ml IM injection of a mixture comprising between about 0.1-9.9 ml of about 0.5-11% proparacaine and between about 0.1-8.4 ml of about 2-10 mg/ml betamethasone. A further embodiment treats an adult HIV patient with between about 1-10 ml IM injection of between about 0.1-9.6 ml of about 0.5-30% benzocaine and between about 0.1-7.9 ml of about 2-10 mg/ml dexamethasone. Yet another embodiment treats an adult HIV patient with between about 1-10 ml IM injection of between about 0.4-9.6 ml of about 0.5-20% chlorotetracaine and between about 0.1-8.0 ml of about 2-10 mg/ml flumethasone. In yet another embodiment, an adult HIV patient is treated with between about 1-10 ml IM injection of a mixture comprising between about 0.1-8.5 ml of about 0.5-18% tetracaine and between about 0.01-7.7 ml of about 4 mg/ml dexamethasone. In yet another embodiment, an adult HIV patient is treated with between about 1-10 ml IM injection of a mixture comprising between about 0.1-8.5 ml of about 0.5-18% fluoroprocaine and between about 0.01-7.7 ml of about 4 mg/ml betamethasone. ,

[22] In a further HIV treatment embodiment, two injections are administered daily over an about 60-120 minute interval for between about 11-18 days. In another embodiment the treatment is administered twice daily for between about 15-18 days. As an example, an adult HIV patient may be treated with two about 2 ml doses at about 60-90 minute intervals for about 11-18 days. During treatment, the patient is further treated with oral electrolyte solution. A child may be treated with about 1 ml doses. HIV patients may require an extended treatment regimen further comprising additional weeks of treatment when the composition are injected twice a day in decreasing days of treatment starting from 4 days and decreasing to three, two and one day treatments. This may be followed by a maintenance regimen of a twice-a-day dosage every 15 days.

[23] More generally, an adult influenza patient is treated with between about 1-10 ml IM injection of a mixture comprising between about 0.3-8.7 ml of about 1-12% bromoprocaine and between about 0.1-7.9 ml of about 2-10 mg/ml betamethasone. In another embodiment, an adult influenza patient is treated with between about 1-10 ml IM injection of a mixture comprising between about 0.1-9.0 ml of about 0.5-15% chlorotetracaine and between about 0.1- 8.4 ml of about 4 mg/ml betamethasone. A further embodiment treats an adult influenza patient with between about 1-10 ml IM injection of a mixture comprising between about 0.3-8.6 ml of about 0.5-14% tetracaine and between about 0.1-8.8 ml of about 2-10 mg/ml betamethasone. Yet another embodiment treats an adult influenza patient with between about 1-5 ml IM injection of a mixture comprising between about 0.2-8.9 ml of about 1-17% chloroprocaine and between about 0.1-7.8 ml of about 4 mg/ml dexamethasone. In yet another embodiment, an adult influenza patient is treated with between about 0.5-10 ml IM injection of a mixture comprising between about 0.2-7.9 ml of about 0.5-22% proparacaine and between about 0.01-9.2 ml of about 4 mg/ml flumethasone. In yet another embodiment, an adult influenza patient is treated with between about 1-10 ml IM injection of a mixture comprising between about 0.1-9.0 ml of about 0.5-15% fluoroprocaine and between about 0.1-8.4 ml of about 4 mg/ml flumethasone.

[24] In a further influenza embodiment, one or two injections are administered daily for between about 1-3 days. When two injections are made, they are administered over an about 60-120 minute interval. As an example, an adult influenza patient is treated with about two 2 ml doses at about 60-90 minute intervals for 1-5 days with oral hydration solution (bottled water 500 ml mixed with Vz electrolyte tablet). A child may be treated with 1 ml doses.

[25] More generally, an adult Dengue Fever patient is treated with between about 1-10 ml IM injection of a mixture comprising between about 0.2-7.9 ml of about 0.5-17% tetracaine and between about 0.1-8.5 ml of about 2-10 mg/ml flumethasone. In another embodiment, an adult Dengue Fever patient is treated with between about 0.1-10 ml IM injection of a mixture comprising between about 0.1-8.8 ml of about 0.5-14% chloroprocaine and between about 0.1- 9.3 ml of about 4 mg/ml fiumethasone. A further embodiment treats an adult Dengue Fever patient with between about 1-10 ml IM injection of a mixture comprising between about 0.2-7.9 ml of about 1-15% bromoprocaine and between about 0.2-9.9 ml of about 4 mg/ml dexamethasone. Yet another embodiment treats an adult Dengue Fever patient with between about 1-10 ml IM injection of a mixture comprising between about 0.1-9.2 ml of about 0.5-15% proparacaine and between about 0.3-9.6 ml of about 4 mg/ml betamethasone. In yet another embodiment, an adult Dengue Fever patient is treated with between about 0.5-10 ml IM injection of a mixture comprising between about 0.1-9.4 ml of about 0.5-33% benzocaine and between about 0.1-8.1 ml of about 2-10 mg/ml betamethasone. Yet another embodiment treats an adult Dengue Fever patient with between about 1-10 ml IM injection of a mixture comprising between about 0.1-9.2 ml of about 0.5-15% fluoroprocaine and between about 0.3-9.6 ml of about 4 mg/ml dexamethasone.

[26] In a further Dengue Fever embodiment, two injections are administered daily for between about 3-5 days. The two injections are administered over an about 60-90 minute interval. As an example, an adult is treated with two about 2 ml doses daily for 3-5 days. During treatment, the patient is further treated with an oral hydration solution. A child may be treated with 1 ml doses.

[27] More generally, patients having any of common colds, herpes, mumps, measles, hepatitis, conjunctivitis, rabies and chickenpox are treated with an IM injection of a mixture comprising between about 0.2-7.9 ml of about 0.5-17% a first ingredient select from the group consisting of chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and between about 0.1-8.5 ml of about 4 mg/ml of a second ingredient selected from the group consisting of dexamethasone, fiumethasone and betamethasone. Such patients are also treated with an IM injection of a mixture comprising between about 0.3-8.6 ml of about 0.5-14% a first ingredient select from the group consisting of procaine, chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and between about 0.1-8.8 ml of about 2-10 mg/ml of a second ingredient selected from the group consisting of betamethasone and fiumethasone. The treatment plans for common colds, herpes, mumps, measles, conjunctivitis, rabies and chickenpox generally involve two injections at about 60-120 minute intervals for between about 1-5 days. For hepatitis, the treatment plan is similar except for the 15-30 day treatment duration. In a further embodiment, the hepatitis patient is treated for 5 days, and then treated daily under lab testing until favorable results are found. Patients treated with a 9:1 ratio of procaine and dexamethasone reported improved results.

[28] Generally, for all treatments, children may be treated by IM injections of between about 0.5-7 ml of the above-described mixtures in the above-described time intervals. In particular embodiments, an adult is injected with about 2 ml of the mixture, while children under 13 are injected with about 1 ml of the mixture. The treatment interval for all treatments can vary, depending on virus, from once every 3 days up to 3-4 per day.

[29] In an embodiment, a composition according to the present invention is made by mixing Chloroprocaine and Dexamethasone Sodium Phosphate. Around 30 mg of Chloroprocaine in 1.5 ml of a 20 mg/ml solution is mixed with around 2 mg of Dexamethasone in 0.5 ml of a 4 mg/ml solution. The total volume of 2 ml comprising the two mixed formulations are gently mixed and aseptically transferred into a sterile 2 ml syringe. Empirical observation indicated that treatment by chloroprocaine and dexamethasone took less time and produced improved results over procaine and dexamethasone.

[30] In an alternate embodiment, 3 ml is taken out of a 30 ml bottle of chloroprocaine (20 mg/ml). Then, 3 ml dexamethasone (4mg/ml) is added into the above-recited chloroprocaine solution bottle. This provides a 9:1 mixture of chloroprocaine and dexamethason. The bottle is gently mixed (shaken) and the solution is ready to be aseptically transferred into a sterile syringe for IM administration. In an embodiment, 2 ml of the solution is administered twice daily at 90 minute intervals to prevent HIV viruses from attaching to and entering host cells in HIV patients for 15 days, followed by administration of four, three and two days per week.

HIV Studies

[31] In both case studies involving HIV patients, the viral load increased after treatment with the invention. However, in both cases the patient experienced relief from the effects of their infections and demonstrated an improvement of their immune systems as demonstrated by an increased CD4 count. Without limiting the invention to any particular theory, it is believed that the composition used in accordance to the invention attacks the HIV virus across the blood brain barrier and in sanctuary sites of the body.

[32] It is believed that only 2% of the HIV viruses are present in the patient's circulating blood. The remainder is believed to reside in sanctuary sites such as the lymph nodes, macrophages, genital tract (semen), nervous tissue (brain and cerebrospinal fluid) and other body tissues. The increase in plasma viral load after treatment is believed to be a result of the penetration of the treatment into the sanctuary sites, followed by release of inactivated virus into the bloodstream. Thus, it is possible for the patient to experience relief from symptoms of the infection and demonstrate an improved immune system, while simultaneously indicate an increased circulatory viral load. It is believed that longer studies will indicate an eventual decrease in circulatory viral load as the virus is further cleansed from the body. It is unknown whether all of the virus may eventually be expelled. It is possible that the virus will not be completely eradicated from the patient, but that viral replication will be contained by the immune system in a carrier state. In this context, it is believed that an inactivated virus is one that is no longer capable of independent attachment to and absorption into host cells.

[33] In accordance with the observed results where the patient shows marked improvement and experiences an increase in CD4 count, while experiencing an increased plasma viral load, it is believed that the plasma viral load has been substantially inactivated. However, because the presence of such viral loads appears to impose no impediment to the recovery of the patient and the patient's immune system, it is believed that of blood from such patients may serve as a vaccine source against the virus. Thus, an HIV patient may be treated in accordance with the invention. Thereafter, the blood of a treated patient may be administered to a healthy patient to induce immunity to the healthy patient against onset of AIDS. Alternatively, the blood of the patient may be used to isolate vaccinating factors, which then can be administered to healthy patients to immunize the healthy patient against the onset of AIDS.

[34] Finally, all references, including any priority documents, cited herein are hereby incorporated by reference. While the present invention has been described in considerable detail, it will be obvious to those skilled in the art that alterations may be made in the device itself or in the procedure for using the device without departing from the concept and scope of the present invention as described in the following claims.

Claims

I claim:

1. A method of treating a patient suffering an ailment selected from the group consisting of influenza, Dengue fever and HIV infection comprising administering to the patient an IM injection of a mixture comprising chloroprocaine and dexamethasone.

2. The method according to claim 1, wherein the mixture is administered once every 3 days up to 4 times per day, and the patient is further treated by oral administration of electrolyte solution.

3. The method according to claim 2, wherein the patient is further treated by administration of an antipyretic selected from the group consisting of aspirin, calpol, paracetamol, acetaminophen and ibuprofen.

4. The method according to claim 3, wherein the mixture is administered twice daily at an interval of between about 60-120 minutes and 500 ml of electrolyte solution is orally administered daily for the duration of the treatment.

5. The method according to claim 1, wherein the ailment is selected from the group consisting of influenza and Dengue fever and treatment was conducted over about 1-5 days.

6. The method according to claim 1, wherein the ailment is HIV infection and treatment is conducted over about 11-18 days.

7. The method according to claim 1, wherein the mixture is an about 1-2 ml dose of a 9:1 mixture of 20 mg/ml chloroprocaine and 4 mg/ml dexamethasone.

8. A method of treating a patient suffering an ailment selected from the group consisting of common colds, influenza, Dengue fever, mumps, measles, hepatitis, rabies, conjunctivitis, chickenpox, herpes, and HIV infection comprising administering to the patient an IM injection of a mixture comprising a first ingredient selected from the group consisting of chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and a second ingredient selected from the group consisting of dexamethasone, flumethasone and betamethasone.

9. The method of claim 8, wherein the mixture is administered twice daily at an interval of between about 60-120 minutes, and the patient is further treated by daily oral administration of about 500 ml of electrolyte solution during the treatment.

10. The method according to claim 9, wherein the patient is further treated by administration of an antipyretic selected from the group consisting of aspirin, calpol, paracetamol, acetaminophen and ibuprofen.

11. The method according to claim 8, wherein the mixture is an about 0.5-10 ml dose of an about 0.1-9.9 ml of an about 0.3-33% of the first ingredient and 0.1-8.8 ml of an about 2-10 mg/ml of the second ingredient.

12. The method according to claim 8, wherein the mixture is an about 1.5-4 ml dose of an about 0.5-3.0 ml of an about 1.5-25% of the first ingredient and an about 1-3.5 ml of an about 4 mg/ml of the second ingredient.

13. The method according to claim 8, wherein the mixture is administered at intervals of between once every three days to four times per day.

14. A method of treating a patient suffering an ailment selected from the group consisting of common colds, influenza, Dengue fever, mumps, measles, hepatitis, rabies, conjunctivitis, chickenpox, herpes, and HIV infection comprising administering an IM injection of a mixture comprising a first ingredient selected from the group consisting of procaine, chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fiuoroprocaine and benzocaine, and a second ingredient selected from the group consisting of flumethasone and betamethasone.

15. The method of claim 14, wherein the mixture is administered at intervals of between once every three days to four times per day, and the patient is further treated by administration of electrolyte solution during the treatment.

16. The method according to claim 15, wherein the patient is further treated by administration of an antipyretic selected from the group consisting of aspirin, calpol, paracetamol, acetaminophen and ibuprofen.

17. The method according to claim 14, wherein the mixture is an about 0.5-10 ml dose of an about 0.1-9.9 ml of an about 0.3-33% of the first ingredient and 0.1-8.8 ml of an about 2-10 mg/ml of the second ingredient.

18. The method according to claim 14, wherein the mixture is an about 1.5-4 ml dose of an about 0.5-3.0 ml of an about 1.5-25% of the first ingredient and an about 1-3.5 ml of an about 4 mg/ml of the second ingredient.

19. The method according to claim 14, wherein the mixture is administered twice daily at an interval of between about 60-120 minutes, and the patient is further treated by daily oral administration of about 500 ml of electrolyte solution during the treatment.

20. The method according to claim 19, wherein the mixture is an about 1-2 ml dose of a 9:1 mixture of 20 mg/ml of the first ingredient and 4 mg/ml of the second ingredient.

21. A method of preventing HIV from attaching to and absorption into a host cell of an HIV patient comprising administering to the patient an IM injection of a mixture comprising a first ingredient selected from the group consisting of chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and a second ingredient selected from the group consisting of dexamethasone, fiumethasone and betamethasone.

22. The method of claim 21, wherein the first ingredient is chloroprocaine, and the second ingredient is dexamethasone, and the mixture is administered twice daily at 90 minute intervals everyday for 15-18 days, and the patient is further treated by administration of electrolyte solution during the treatment.

23. The method according to claim 21, wherein the mixture is administered twice daily administration at 60-120 minute intervals for 11-18 days, followed by two administrations of the mixture a day for 4 days of a first week, three days of a second week and two days of a third week, followed by a maintenance regimen of two administrations of the mixture one day every two weeks.

24. The method according to claim 21, wherein the mixture is an about 1.5-4 ml dose of an about 0.5-3.0 ml of an about 1.5-25% of the first ingredient and an about 1-3.5 ml of an about 4 mg/ml of the second ingredient.

25. The method according to claim 21, wherein the mixture is an about 1-2 ml dose of a 9:1 mixture of 20 mg/ml of the first ingredient and 4 mg/ml of the second ingredient and the mixture is administered twice daily at an interval of between about 60-120 minutes, and the patient is further treated by daily oral administration of about 500 ml of electrolyte solution during the treatment.

26. A method of penetrating sanctuary sites in an HIV patient to inactivate HIV comprising administering to the patient an IM injection of a mixture comprising a first ingredient selected from the group consisting of chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and a second ingredient selected from the group consisting of dexamethasone, flumethasone and betamethasone.

27. The method of claim 26, wherein the first ingredient is chloroprocaine, and the second ingredient is dexamethasone, and the mixture is administered twice daily at 90 minute intervals everyday for 15-18 days, and the patient is further treated by administration of electrolyte solution during the treatment.

28. The method according to claim 26, wherein the mixture is administered twice daily at 60-120 minute intervals for 11-18 days, followed by two administrations of the mixture a day for 4 days of a first week, three days of a second week and two days of a third week, followed by a maintenance regimen of two administrations of the mixture one day every two weeks.

29. The method according to claim 26, wherein the mixture is an about 1.5-4 ml dose of an about 0.5-3.0 ml of an about 1.5-25% of the first ingredient and an about 1-3.5 ml of an about 4 mg/ml of the second ingredient.

30. The method according to claim 26, wherein the mixture is an about 1-2 ml dose of a 9:1 mixture of 20 mg/ml of the first ingredient and 4 mg/ml of the second ingredient and the mixture is administered twice daily at an interval of between about 60-120 minutes, and the patient is further treated by daily oral administration of about 500 ml of electrolyte solution during the treatment.

31. A method of providing an HIV vaccine comprising administering to an HIV infected patient an IM injection of a mixture comprising a first ingredient selected from the group consisting of chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine, proparacaine, fluoroprocaine and benzocaine, and a second ingredient selected from the group consisting of dexamethasone, flumethasone and betamethasone until the patient demonstrates an immune system recovery and then extracting blood from the patient.

32. The method of claim 31, wherein the first ingredient is chloroprocaine, and the second ingredient is dexamethasone, and the mixture is administered twice daily at 90 minute intervals everyday for 15-18 days, and the patient is further treated by administration of electrolyte solution during the treatment.

33. The method according to claim 31, wherein the vaccinating factors are further isolated from the blood of the patient.

34. The method according to claim 31, wherein the mixture is an about 1.5-4 ml dose of an about 0.5-3.0 ml of an about 1.5-25% of the first ingredient and an about 1-3.5 ml of an about 4 mg/ml of the second ingredient.

35. The method according to claim 31, wherein the mixture is an about 1-2 ml dose of a 9:1 mixture of 20 mg/ml of the first ingredient and 4 mg/ml of the second ingredient and the mixture is administered twice daily at an interval of between about 60-120 minutes for about 11- 18 days, followed by two administrations of the mixture a day for 4 days of a first week, three days of a second week and two days of a third week, and the patient is further treated by daily oral administration of about 500 ml of electrolyte solution during the treatment.